Literature DB >> 20600672

Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma.

K Y Kim1, W K Ju, B Hegedus, D H Gutmann, M H Ellisman.   

Abstract

The purpose of this study was to investigate the progression of changes in retinal ganglion cells and optic nerve glia in neurofibromatosis-1 (NF1) genetically-engineered mice with optic glioma. Optic glioma tumors were generated in Nf1+/- mice lacking Nf1 expression in GFAP+ cells (astrocytes). Standard immunohistochemistry methods were employed to identify astrocytes (GFAP, S100beta), proliferating progenitor cells (sox2, nestin), microglia (Iba1), endothelial cells (CD31) and retinal ganglion cell (RGC) axons (Neurofilament 68k) in Nf1+/-, Nf1(GFAP)CKO (wild-type mice with Nf1 loss in glial cells), and Nf1+/-(GFAP)CKO (Nf1+/- mice with Nf1 loss in glial cells) mice. Ultrastructural changes in the optic chiasm and nerve were assessed by electron microscopy (EM). RGC were counted in whole retina preparations using high-resolution, mosaic confocal microscopy following their delineation by retrograde FluoroGold labeling. We found that only Nf1+/-(GFAP)CKO mice exhibited gross pre-chiasmatic optic nerve and chiasm enlargements containing aggregated GFAP+/nestin+ and S100beta+/sox2+ cells (neoplastic glia) as well as increased numbers of blood vessels and microglia. Optic gliomas in Nf1+/-(GFAP)CKO mice contained axon fiber irregularities and multilamellar bodies of degenerated myelin. EM and EM tomographic analyses showed increased glial disorganization, disoriented axonal projections, profiles of degenerating myelin and structural alterations at nodes of Ranvier. Lastly, we found reduced RGC numbers in Nf1+/-(GFAP)CKO mice, supporting a model in which the combination of optic nerve Nf1 heterozygosity and glial cell Nf1 loss results in disrupted axonal-glial relationships, subsequently culminating in the degeneration of optic nerve axons and loss of their parent RGC neurons. Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20600672      PMCID: PMC2926211          DOI: 10.1016/j.neuroscience.2010.06.017

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  68 in total

Review 1.  Retinal ganglion cell disorders: types and treatments.

Authors:  Leonard A Levin; Lynn K Gordon
Journal:  Prog Retin Eye Res       Date:  2002-09       Impact factor: 21.198

2.  Transform-based backprojection for volume reconstruction of large format electron microscope tilt series.

Authors:  Albert Lawrence; James C Bouwer; Guy Perkins; Mark H Ellisman
Journal:  J Struct Biol       Date:  2006-02-17       Impact factor: 2.867

Review 3.  Ultrastructural pathology of glial brain tumors revisited: a review.

Authors:  P P Liberski; R Kordek
Journal:  Ultrastruct Pathol       Date:  1997 Jan-Feb       Impact factor: 1.094

4.  Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing?

Authors:  Darcy H Wolsey; Scott A Larson; Donnel Creel; Robert Hoffman
Journal:  J AAPOS       Date:  2006-08       Impact factor: 1.220

5.  Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo.

Authors:  Debasish Banerjee; Balazs Hegedus; David H Gutmann; Joel R Garbow
Journal:  Neuroimage       Date:  2007-02-23       Impact factor: 6.556

6.  Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.

Authors:  Yuan Zhu; Takayuki Harada; Li Liu; Mark E Lush; Frantz Guignard; Chikako Harada; Dennis K Burns; M Livia Bajenaru; David H Gutmann; Luis F Parada
Journal:  Development       Date:  2005-12       Impact factor: 6.868

Review 7.  Late-onset optic pathway tumors in children with neurofibromatosis 1.

Authors:  R Listernick; R E Ferner; L Piersall; S Sharif; D H Gutmann; J Charrow
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

8.  Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

Authors:  R Listernick; J Charrow; M Greenwald; M Mets
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

9.  SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity.

Authors:  Rosaria Maria Rita Gangemi; Fabrizio Griffero; Daniela Marubbi; Marzia Perera; Maria Cristina Capra; Paolo Malatesta; Gian Luigi Ravetti; Gian Luigi Zona; Antonio Daga; Giorgio Corte
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

Review 10.  Neurobiology of glaucomatous optic neuropathy: diverse cellular events in neurodegeneration and neuroprotection.

Authors:  Martin B Wax; Gülgün Tezel
Journal:  Mol Neurobiol       Date:  2002-08       Impact factor: 5.590

View more
  17 in total

1.  An 80-year experience with optic nerve glioma cases at the Armed Forces Institute of Pathology: evolution from museum to molecular evaluation suggests possibe interventions in the cellular senescence and microglial pathways (an American Ophthalmological Society thesis).

Authors:  J Douglas Cameron; Fausto J Rodriguez; Elisabeth Rushing; Iren Horkayne-Szakaly; Charles Eberhart
Journal:  Trans Am Ophthalmol Soc       Date:  2014

Review 2.  The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Authors:  Souvik Karmakar; Karlyne M Reilly
Journal:  CNS Oncol       Date:  2016-12-21

Review 3.  The role of microglia and macrophages in glioma maintenance and progression.

Authors:  Dolores Hambardzumyan; David H Gutmann; Helmut Kettenmann
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

4.  Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset.

Authors:  Mark Jentoft; Caterina Giannini; Ling Cen; Bernd W Scheithauer; Bridget Hoesley; Jann N Sarkaria; Patrice C Abell-Aleff; Erika F Rodriguez; Ying Li; Fausto J Rodriguez
Journal:  Int J Clin Exp Pathol       Date:  2010-12-12

Review 5.  Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.

Authors:  Morgan E Freret; David H Gutmann
Journal:  J Neurosci Res       Date:  2018-04-28       Impact factor: 4.164

Review 6.  Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.

Authors:  Robert Listernick; Rosalie E Ferner; Grant T Liu; David H Gutmann
Journal:  Ann Neurol       Date:  2007-03       Impact factor: 10.422

7.  Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.

Authors:  Joseph A Toonen; Yu Ma; David H Gutmann
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

8.  The impact of coexisting genetic mutations on murine optic glioma biology.

Authors:  Aparna Kaul; Joseph A Toonen; Scott M Gianino; David H Gutmann
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

Review 9.  Optic Pathway Gliomas in Neurofibromatosis Type 1.

Authors:  Cynthia J Campen; David H Gutmann
Journal:  J Child Neurol       Date:  2018-01       Impact factor: 1.987

10.  Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.

Authors:  Kelly A Diggs-Andrews; Jacquelyn A Brown; Scott M Gianino; Joshua B Rubin; David F Wozniak; David H Gutmann
Journal:  Ann Neurol       Date:  2014-02-06       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.